Current perspectives on TRK fusion-positive thyroid cancers
Current perspectives on TRK fusion-positive thyroid cancers
Clinical summary video and slides
Clinical summary video and slides
Prof. Ezra Cohen
In this 5-min video update, Prof. Ezra Cohen summarises current perspectives on the diagnosis and treatment of TRK fusion-positive cancers. He discusses US and European guidelines, two recent key publications and larotrectinib data presented at the American Thyroid Association annual meeting.
Clinical takeaways:
- NTRK fusions are more common in paediatric compared to adult thyroid cancers, testing is warranted in both populations
- NTRK2 fusions have not been seen in thyroid cancer, only NTRK1 and NTRK3 fusions
- Larotrectinib and entrectinib are two approved TRK inhibitors showing durable responses with favourable safety profiles
- There are differences in the prognosis of NTRK1 vs NTRK3 fusion-positive thyroid cancer and differentiated vs anaplastic thyroid cancers
NTRK fusions in thyroid cancer
|
5 min
|
Dec 2022
I agree that this educational programme:
This educational programme is supported by an Independent Medical Education Grant from Bayer
PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.
Other programmes of interest
Other programmes developed by Prof. Ezra Cohen

Prof. Ezra Cohen
Medical Oncologist
Moores Cancer Center, San Diego
United States (US)